Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2017 May;20(2):64.
doi: 10.1136/eb-2016-102606. Epub 2017 Feb 28.

Changing response rates in clinical trials of depression: how did the introduction of DSM-III and DSM-III-R influence the outcome?

Konstantinos N Fountoulakis  1
Affiliations
Comment

Changing response rates in clinical trials of depression: how did the introduction of DSM-III and DSM-III-R influence the outcome?

Konstantinos N Fountoulakis. Evid Based Ment Health. 2017 May.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Competing interests: KNF has received grants and served as consultant, advisor or CME speaker for the following entities: AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Ferrer, Gedeon Richter, Janssen, Lundbeck, Otsuka, Pfizer, the Pfizer Foundation, Sanofi-Aventis, Servier, Shire and others.

Figures

Figure 1
Figure 1
Distant-weighted least squares regression lines of Cohen's D concerning the active drug arm, the placebo arm and their difference. Note that this graph is only to give a visual impression of the data since such an analysis violates the within studies randomisation.
See this image and copyright information in PMC

Comment on

References

    1. Furukawa TA, Cipriani A, Atkinson LZ, et al. . Placebo response rates in antidepressant trials: a systematic review of published and unpublished double-blind randomised controlled studies. Lancet Psychiatry 2016;3:1059–66. 10.1016/S2215-0366(16)30307-8 - DOI - PubMed
    1. Fountoulakis KN. DSM-III-R change in definition might have affected placebo response to antidepressants. Lancet Psychiatry 2017;4:21–2. 10.1016/S2215-0366(16)30372-8 - DOI - PubMed
    1. Cipriani A, Furukawa TA, Atkinson LZ, et al. . DSM-III-R change in definition might have affected placebo response to antidepressants—authors’ reply. Lancet Psychiatry 2017;4:22–3. 10.1016/S2215-0366(16)30415-1 - DOI - PubMed
    1. Fountoulakis KN, Samara MT, Siamouli M. Burning issues in the meta-analysis of pharmaceutical trials for depression. J Psychopharmacol (Oxford) 2014;28:106–17. 10.1177/0269881113504014 - DOI - PubMed
    1. Huedo-Medina TB, Johnson BT, Kirsch I. Kirsch, et al.'s (2008) calculations are correct: reconsidering Fountoulakis & Moller's re-analysis of the Kirsch data. Int J Neuropsychopharmacol 2012;15:1193–8. 10.1017/S1461145711001878 - DOI - PubMed

MeSH terms